18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
19:32 , Jul 13, 2018 |  BC Week In Review  |  Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
23:03 , Jul 2, 2018 |  BC Extra  |  Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
20:14 , Jun 15, 2018 |  BC Week In Review  |  Financial News

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million on June 8 in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment....
00:49 , Nov 10, 2017 |  BC Innovations  |  Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
20:36 , Apr 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Allosteric en-ABL-ement

Novartis AG has developed a new strategy to prevent leukemias from becoming resistant to its CML drugs against BCR-ABL . Rather than combining the inhibitors with other classes of cancer therapies, the company is doubling...